[Intermediate-risk prostate cancer treated with exclusive external irradiation: Focus on anatomical sites of recurrence in two French trials].
Cancer de la prostate de risque intermédiaire traité par irradiation externe exclusive : focus sur les sites anatomiques de récidive dans deux essais français.
Biochemical recurrence
Cancer de la prostate de risque intermédiaire
Intermediate prostate cancer risk
PET-CT
Radiotherapy
Radiothérapie
Récidive biochimique
TEP-choline
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
24
06
2021
revised:
12
11
2021
accepted:
24
11
2021
pubmed:
18
6
2022
medline:
17
8
2022
entrez:
17
6
2022
Statut:
ppublish
Résumé
Retrospective description of anatomical sites of relapse based on (18F)-choline PET-CT, (68Ga)-prostatic specific-membrane antigen PET-CT, bone scan, and prostate magnetic resonance imaging (MRI) data. From two French prospective cohorts, patients treated with exclusive radiotherapy for an intermediate-risk cancer were identified during their follow-ups. They were included if they presented a rising of the prostate-specific antigen (PSA) associated with the realization of an imaging showing the sites of recurrences. Two hundred and sixty-three patients were included. After a median follow-up of 76 months (interquartile range [IQR] 67-95), 65 patients had biochemical recurrence and positive imaging. The median nadir PSA was 0.6ng/mL and the median PSA at recurrence was 3.4ng/mL. A single lesion was found in 48% of cases, 2 to 4 lesions in 43% of cases and more than 4 lesions in 9% of cases. The sites of relapse identified were prostate (37/65), prostate only (19/65), seminal vesicles (9/65) Pelvic nodes (35/65), extrapelvic nodes (15/65) and bone (13/65). The majority of relapses presented as a single lesion localized in the pelvis.
Identifiants
pubmed: 35715355
pii: S1278-3218(22)00031-2
doi: 10.1016/j.canrad.2021.11.025
pii:
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Choline
N91BDP6H0X
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
647-653Informations de copyright
Copyright © 2022. Published by Elsevier Masson SAS.